An observational study in Respiratory Distress Syndrome, Adult, Critical Illness and Mechanical Ventilation Complication, sponsored by University of Oxford. Status unknown at 1 site in United Kingdom. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-02-07.
Sponsored by University of Oxford · Observational
Among 47 studies in Respiratory Distress Syndrome with a site in United Kingdom — 10 open to participants now, 13 under way, 3 of them phase 3. Respiratory Distress Syndrome · United Kingdom.
Among the 47 studies in Respiratory Distress Syndrome with a site in United Kingdom, this one is the 11th largest by planned enrollment of the 15 observational ones that give a count, is one of 3 that started in 2017, is one of 16 observational ones, and was the 18th registered.
1,387 studies on the registry are indexed under Respiratory Distress Syndrome; 283 are open to participants now.
Browse Respiratory Distress Syndrome studies →10 of the 47 studies in Respiratory Distress Syndrome with a site in United Kingdom are open now. Recruiting first, the newest first:
Guy's and St Thomas' NHS Foundation Trust · Sites in United Kingdom
Ages 18–100
Aerogen Pharma Limited · Sites in United Kingdom, United States, Canada
Ages 1 hrs–24 hrs
BioAegis Therapeutics Inc. · Sites in United Kingdom, United States, Belgium and 10 more countries
Ages 18+
King's College Hospital NHS Trust · Sites in United Kingdom
Ages 34 wk–38 wk
Guy's and St Thomas' NHS Foundation Trust · Sites in United Kingdom
Ages 17+
A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →
Of the 194 Respiratory Distress Syndrome studies recruiting now, 118 (61%) set no upper age limit and 48 (25%) stop at 75 or younger; 51 take children under 18; 9 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
47 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 9 · Phase 3 8 · Phase 4 2
First in 2003; this study’s year is marked. 3 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 80 is below the median of 100 across 475 observational studies indexed under Respiratory Distress Syndrome.
Median enrollment 90 across the 31 interventional studies, 132 across the 15 observational. Of the 27 that completed or were terminated, 6 (22%) have results posted.
This tab as a report to print or save as PDF → With an account.
16 of 47 have an industry lead sponsor. The 10 most frequent:
University of Oxford is the lead sponsor of 812 studies on the registry; 119 are open to participants now.
University of Oxford has 2 studies filed under Respiratory Distress Syndrome — fewer than ten, so there is no comparison to draw.
8 of the studies in Respiratory Distress Syndrome with a site in United Kingdom that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06776783Phase 3Aerogen Pharma LimitedSafety and Efficacy of APC-0101 in Preterm Infants With Respiratory Distress Syndrome | 2027-05 |
| NCT06014138Phase 3Guy's and St Thomas' NHS Foundation TrustVolatile Sedation for Patients With the Acute Respiratory Distress Syndrome | 2027-07-31 |
| NCT05624450Phase 3AstraZenecaEfficacy and Safety of Tozorakimab in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen | 2027-11-04 |
| NCT05388708University of MichiganARDS in Children and ECMO Initiation Strategies Impact on Neurodevelopment (ASCEND) | 2027-06-30 |
| NCT07580781Guy's and St Thomas' NHS Foundation TrustFeasibility of Protocolised Analgosedation in ECMO | 2027-08-31 |
Add all 8 to your calendar (.ics) → With an account.
Among the 47 studies in Respiratory Distress Syndrome with a site in United Kingdom, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a feasibility study of the use of a novel technique called 'Inspiwave' to measure heart and lung function in adult patients in critical care.
The preliminary work has already been undertaken in animal models and in healthy volunteers. The ultimate aim of this study is to develop a clinical tool for measuring (and therefore being able to make treatment changes based on) indices of heart and lung function in critical care patients. This study is the first assessment of the technique in this population, and whilst we know it works in patients undergoing general anaesthesia, we now need to assess whether Inspiwave can be used at all in critical care patients who may have much more physiological derangement. The purpose of this phase of the research is to determine whether it is feasible to use Inspiwave in critical care.
Inspiwave generates a sinusoidally modulated tracer gas signal in the inspired air. It also measures the resulting signal in the expired air. The unique handling of this signal by the patient can used be to derive key variables related to cardiopulmonary function such as lung volume, pulmonary blood flow, the deadspace (wasted ventilation) and the degree to which ventilation and blood flow are non-uniform. These are 'vital signs' in sick patients, yet are currently technically difficult to measure, particularly non-invasively.
-mechanically ventilated patients in a critical care area
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
patients are monitored with the Inspiwave device. A low dose inert tracer gas is added to the inspred air
Production of any numerical values of effective lung volume and pulmonary blood flow
We wish to know whether the technique can be applied, and whether the signal to noise ratio allows computation of the variables of interest. It is yet unclear whether or not the device can operate in a critical care environment.
Time frame: Sept 2020
Comparison of measurements of effective lung volume and pulmonary blood flow under changes in observed clinical condition.
To observe if changes in clinical condition can be detected by the device.
Time frame: Sept 2020
Signal:noise ratio of measured data.
If values for effective lung volume and pulmonary blood flow can be produced, are these with adequate signal:noise ratio to allow inverse modelling.
Time frame: Sept 2020
Plan to share: No
No publications or documents are linked to this record.
Started Oct 2017 (actual). Primary completion is estimated for Sep 2019, 23 months after the start.
Of 225 non-industry observational studies under Respiratory Distress Syndrome, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 47. This study's planned 23 months is close to that.
Counting every sponsor, half of 231 studies reached it within 24 months; a quarter within 12 and three quarters within 49.
How these figures are worked out, and which studies are left out of them.
This study is status unknown, as verified in Jan 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Respiratory Distress Syndrome →